Invea is excited to attend BIO-Europe in Sweden! We are focused on advancing our AI powered pipeline for immune-mediated inflammatory diseases (IMIDs), including INVA8001 a Phase 2 oral small molecule that targets the clinically validated SCF-c-KIT axis for mast cell disorders and INVA8003, an oral multi-inflammasome inhibitor. We're excited to connect with global innovators focused on addressing areas of urgent unmet therapeutic needs. Please message?Aman Kant to explore how we can collaborate. #BIOEurope #Invea #IMIDs #AIDrugDiscovery #Innovation
Invea Therapeutics
生物技术
Guilford，Connecticut 744 位关注者
Developing Innovative Small-molecule Oral Therapies for Immune-Mediated Inflammatory Diseases, or IMIDs
关于我们
Overview We are a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs. Our aim is to develop oral, safe and effective small-molecule therapies that control inflammation, prevent tissue damage, improve quality of life and achieve long-term disease remission. We believe that the lack of an in-depth understanding of the pathophysiological mechanisms underlying immune-mediated inflammation has restricted therapeutic options for several IMIDs to merely symptomatic interventions, with limited effectiveness. Our drug discovery and development approach combines artificial intelligence, or AI, and machine learning, or ML, with our team’s extensive experience and expertise, to decode the mechanisms and pathways that drive the initiation and progression of inflammation for patients with IMIDs. We currently have two product candidates, INVA8001, which we plan to progress into Phase 2b of clinical development, and INVA8003, which is in the early stage preclinical development. We believe that our product candidates, INVA8001 and INVA8003, if approved, can potentially transform the treatment of several IMIDs, such as atopic dermatitis, or AD, and chronic urticaria, or CU, which are characterized by limited or no available therapeutic options or patient populations that are unresponsive, partially responsive or develop resistance to currently available therapies. INVA8001 is designed as an oral, small molecule, highly selective and potent inhibitor of chymase, a key mediator of mast cells driving inflammation, epithelial barrier damage and fibrosis.
- 网站
-
https://www.inveatx.com
Invea Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Guilford，Connecticut
- 类型
- 私人持股
- 创立
- 2021
- 领域
- Drug Discovery 、Target Discovery、Inflammation、Immune-mediated inflammatory diseases、Oral small molecules、Atopic dermatitis、Chronic urticaria和IMIDs
地点
-
主要
获取路线
2614 Boston Post Rd
Suite #33AR
US，Connecticut，Guilford，06437
Invea Therapeutics员工
-
Kerrie Brady
-
Michael Aiello, CPA
Chief Financial Officer at Invea Therapeutics, Inc
-
Sameer Sharma
Senior Vice President & Head of Translational Research at Invea Therapeutics | AI Enthusiast | BioPharma & Healthcare Consultant | SME
-
Aman Kant
Seasoned executive and entrepreneur with expertise at the intersection of Artificial Intelligence and Drug Discovery & Development
动态
-
We are excited to announce that our CEO,?Krishnan Nandabalan, will be speaking at the 6th Inflammasome Therapeutics Summit this week! We can’t wait to share insights on our INVA8003 program - a differentiated small molecule pan inflammasome inhibitor targeting ASC to tackle chronic inflammation. This innovative approach has the potential to make a real difference in treating immune-mediated inflammatory diseases, and we look forward to connecting with others in the field to explore new possibilities!
With only one week to go until the 6th Annual Inflammasome Therapeutics Summit, now is truly your last opportunity to register for this unmissable event: https://ter.li/0y4ztz Intentionally designed to be niche and focused, ensuring you don’t get lost in a sea of attendees and prioritizing in-depth discussions over basic introductions.?Partake in advanced tactical?and?strategic conversations?with an engaged audience of inflammasome experts who share your passion and commitment to advancing inflammasome therapeutics to the patients who need them most. Don't miss out on this opportunity to be at the forefront of inflammasome therapeutics https://ter.li/0y4ztz
-
-
Happy International Women's Day! Today and every day, we celebrate and honor the inspiring women who drive progress, innovation, and continue to make a difference in the world. From shaping the future of healthcare innovation to breaking barriers in every field, your dedication, expertise, and passion are invaluable assets that propel us forward. Let's continue to celebrate and uplift women, creating a more inclusive and diverse industry where everyone can thrive. Together, we can achieve extraordinary advancements and shape a brighter future for all. #InternationalWomensDay #WomenInSTEM #BiotechInnovation #DiversityandInclusion
-
-
Understanding Atopic Dermatitis Did you know atopic dermatitis (AD) is a common skin condition that causes itchiness and inflammation? It's the most prevalent form of eczema, often starting in childhood and possibly continuing into adulthood.? AD is a multifactorial disease recognized as an immune-mediated inflammatory disorder (IMID). It shares a foundational mechanism involving dysregulated immune responses and chronic inflammation with other IMIDs. However, many perceive it as an ‘outside-in’ disorder in which skin barrier dysfunction precedes and triggers immune dysregulation, leading to characteristic inflammation.? ? AD is one of the most prevalent IMIDs, which Invea is addressing with INVA8001, an oral small molecule chymase inhibitor inhibiting the SCF-Ckit axis for decreasing the viability of mast cell survival and proliferation and, therefore, the progression of inflammation which may lead to fibrosis.? ? #AtopicDermatitisAwareness #SkinHealth #IMIDs #inflammatory
-
-
Congratulations to our very own Dr. Sameer Sharma! The dedication and expertise he brings to our team have been instrumental in achieving great milestones. Most recently, his work in immune-mediated inflammatory diseases, or IMIDs, has helped shape a compelling pipeline of candidates for Invea Therapeutics. Dr. Sharma has been at the forefront of AI-augmented target analysis, bringing innovative approaches to enhance and reshape the landscape of our work. Notably, his contributions extend beyond the lab, as he seamlessly translates these advancements into our Clinical Programs. The fusion of AI insights with clinical applications is a testament to Dr. Sharma's commitment to pushing boundaries and creating meaningful outcomes for the IMIDs community. Please take a moment to celebrate this achievement with us by checking out the details in the linked post. Dr. Sharma's commitment to excellence is an inspiration to us all, and we're proud to have him as a valuable member of our team. #Congratulations #Milestone #TeamSuccess #Excellence #DrSameerSharma https://lnkd.in/ehuqhZrZ
Let's give a standing ovation to Mr. Sameer Sharma, Senior Vice President & Head of Translational Research at Invea Therapeutics. His transformative work in translational research is making waves in the industry. Congratulations, Sameer! ?? https://lnkd.in/eqFNcMqb #TradeFlock #inveatherapeutics #lifesciences #leaders #newedition #wednesday #inspiration #motivation #achivement #latestedition #magazine #sucessful #InnovativeLeader
-
-
Happy Holidays from our Team to Yours! ? As another transformative year for Invea comes to a close, we want to take a moment to express our heartfelt gratitude to our team, partners and supporters. As we look forward to the new year, we remain committed to pushing the boundaries of science and technology to advance patient healthcare. May your holidays be filled with joy, peace, and moments of inspiration. Here's to a brighter, healthier future ahead!? ? Warm wishes from The Invea Team ?
-